Skip to main content

Table 2 Summary of biomarker measures used to estimate biological aging

From: Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons

 

Vaccine cohort

CLSA

Female

Male

Female

Male

(N = 190)

(N = 102)

(N = 1928)

(N = 1938)

Albumin (ALB), g/L

42.5 ± 1.09 [-0.25**]

42.8 ± 1.07 [- 0.4***]

39.6 ± 1.07 [- 0.14***]

39.7 ± 1.07 [- 0.15***]

Alanine aminotransferase (ALT), U/L

13.2 ± 1.60 [- 0.26**]

15.0 ± 1.51 [- 0.45***]

18.5 ± 1.45 [- 0.13***]

21.4 ± 1.46 [- 0.23***]

Creatinine (CREAT), µmol/L

72.0 ± 1.27 [0.15]

87.4 ± 1.32 [0.02]

72.0 ± 1.21 [0.15***]

91.2 ± 1.23 [0.16***]

Ferritin (FERR), µg/L

52.4 ± 2.19 [- 0.2*]

78.7 ± 2.43 [- 0.22]

104.5 ± 2.17 [- 0.04*]

159.2 ± 2.22 [- 0.04]

Thyroxine (T4), pmol/L

16.4 ± 1.24 [- 0.02]

15.7 ± 1.28 [0.26*]

15.4 ± 1.19 [0.06**]

14.9 ± 1.16 [0.04]

Cholesterol (CHOL), mmol/L

4.7 ± 1.25 [- 0.13]

4.2 ± 1.26 [- 0.29*]

5.3 ± 1.24 [- 0.09***]

4.5 ± 1.27 [- 0.11***]

High-density lipoprotein (HDL), mmol/L

1.4 ± 1.30 [0.07]

1.2 ± 1.31 [0.23]

1.6 ± 1.33 [0.02]

1.3 ± 1.34 [0.06*]

Triglycerides (TRIG), mmol/L

1.6 ± 1.51 [- 0.22*]

1.8 ± 1.71 [- 0.51***]

1.5 ± 1.58 [- 0.03]

1.5 ± 1.65 [- 0.11***]

Tumour necrosis factor (TNF)a, pg/mL

11.2 ± 1.37 [0.19*]

12.1 ± 1.42 [- 0.03]

1.1 ± 1.43 [0.21***]

1.1 ± 1.39 [0.23***]

Interleukin 6 (IL-6)a, pg/mL

3.0 ± 2.79 [0.14]

2.9 ± 1.99 [0.05]

2.3 ± 1.78 [0.16***]

2.3 ± 1.77 [0.24***]

  1. The geometric mean ± standard deviation is presented for each biomarker measure. The correlation with chronological age (shown in square brackets) represents the standardized coefficient for age from a fixed (ie. CLSA) or mixed effect model including the random intercept for participant (ie. vaccine cohort); significance as follows: ***, p < 0.001; **, p < 0.01; *, p < 0.05
  2. arepresents the concentrations prior to rescaling